Company intelligence / Profile preview

InMed Pharmaceuticals Inc.

Vancouver, British Columbia, Canadainmedpharma.com ↗

Ownership: Public · INM
Employees: ~13
Development stage: Phase 2

Overview

InMed has completed a Phase 2 clinical trial for INM-755 in epidermolysis bullosa. The company is also developing preclinical programs for Alzheimer's disease and age-related macular degeneration. Recent research demonstrated cannabinol's anti-inflammatory effects for treating skin diseases.

Therapeutic areas: OphthalmologyDermatologyNeurology
Modalities: Small moleculesCannabinoidsCannabinoid analogs
Industry: Biotech

Drug pipeline

9 assets

cannabinol

8 more assets in the full pipeline.

Request access →

Financials

Market cap: $2.4M
Total revenue: $2.1B
Enterprise value: $-2.2B

Beyond the preview

Go deeper on InMed Pharmaceuticals Inc..

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on InMed Pharmaceuticals Inc..

Explore the full profile